BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 32200338)

  • 1. Differentiate aquaporin-4 antibody negative neuromyelitis optica spectrum disorders from multiple sclerosis by multimodal advanced MRI techniques.
    Zhang N; Sun J; Wang Q; Qin W; Zhang X; Qi Y; Yang L; Shi FD; Yu C
    Mult Scler Relat Disord; 2020 Jun; 41():102035. PubMed ID: 32200338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromyelitis optica spectrum disorder and multiple sclerosis: Differentiation by a multimodal approach.
    Ota M; Sato N; Okamoto T; Noda T; Araki M; Yamamura T; Kunugi H
    Mult Scler Relat Disord; 2015 Nov; 4(6):515-20. PubMed ID: 26590657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of probabilistic tractography and tract-based spatial statistics for assessing optic radiation damage in patients with autoimmune inflammatory disorders of the central nervous system.
    Kuchling J; Backner Y; Oertel FC; Raz N; Bellmann-Strobl J; Ruprecht K; Paul F; Levin N; Brandt AU; Scheel M
    Neuroimage Clin; 2018; 19():538-550. PubMed ID: 29984162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early and extensive spinal white matter involvement in neuromyelitis optica.
    Hayashida S; Masaki K; Yonekawa T; Suzuki SO; Hiwatashi A; Matsushita T; Watanabe M; Yamasaki R; Suenaga T; Iwaki T; Murai H; Kira JI
    Brain Pathol; 2017 May; 27(3):249-265. PubMed ID: 27082714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders.
    Yang L; Li H; Xia W; Quan C; Zhou L; Geng D; Li Y
    Eur Radiol; 2020 Mar; 30(3):1470-1479. PubMed ID: 31748853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of brain and spinal cord magnetic resonance imaging features in neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody.
    Fan M; Fu Y; Su L; Shen Y; Wood K; Yang L; Liu Y; Shi FD
    Mult Scler Relat Disord; 2017 Apr; 13():58-66. PubMed ID: 28427704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microstructural white matter abnormalities in multiple sclerosis and neuromyelitis optica spectrum disorders: Evaluation by advanced diffusion imaging.
    Kato S; Hagiwara A; Yokoyama K; Andica C; Tomizawa Y; Hoshino Y; Uchida W; Nishimura Y; Fujita S; Kamagata K; Hori M; Hattori N; Abe O; Aoki S
    J Neurol Sci; 2022 May; 436():120205. PubMed ID: 35259556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffusion tensor imaging of normal-appearing white matter in patients with neuromyelitis optica spectrum disorder and multiple sclerosis.
    Kim SH; Kwak K; Hyun JW; Joung A; Lee SH; Choi YH; Lee JM; Kim HJ
    Eur J Neurol; 2017 Jul; 24(7):966-973. PubMed ID: 28643955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population.
    Silveira F; Pappolla A; Sánchez F; Marques VD; de Castillo IS; Tkachuk V; Caride A; Castillo MC; Cristiano E; Cruz CA; Diégues Serva GB; Dos Santos AC; Moreira CL; López PA; Patrucco L; Molina O; Pettinicchi JP; Carnero Contentti E; Rojas JI
    Mult Scler Relat Disord; 2020 Jul; 42():102049. PubMed ID: 32251869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
    Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
    Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodal magnetic resonance imaging quantification of gray matter alterations in relapsing-remitting multiple sclerosis and neuromyelitis optica spectrum disorder.
    Andica C; Hagiwara A; Yokoyama K; Kato S; Uchida W; Nishimura Y; Fujita S; Kamagata K; Hori M; Tomizawa Y; Hattori N; Aoki S
    J Neurosci Res; 2022 Jul; 100(7):1395-1412. PubMed ID: 35316545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
    Kim SM; Waters P; Woodhall M; Kim JY; Kim JE; Yang JW; Kim JS; Sung JJ; Park KS; Lee KW
    Mult Scler; 2013 Jul; 19(8):1060-7. PubMed ID: 23329699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.
    Juryńczyk M; Tackley G; Kong Y; Geraldes R; Matthews L; Woodhall M; Waters P; Kuker W; Craner M; Weir A; DeLuca GC; Kremer S; Leite MI; Vincent A; Jacob A; de Sèze J; Palace J
    J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):132-136. PubMed ID: 27951522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reappraisal of brain MRI features in patients with multiple sclerosis and neuromyelitis optica according to anti-aquaporin-4 antibody status.
    Matsushita T; Isobe N; Piao H; Matsuoka T; Ishizu T; Doi H; Masaki K; Yoshiura T; Yamasaki R; Ohyagi Y; Kira J
    J Neurol Sci; 2010 Apr; 291(1-2):37-43. PubMed ID: 20122699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping white matter damage distribution in neuromyelitis optica spectrum disorders with a multimodal MRI approach.
    Cacciaguerra L; Rocca MA; Storelli L; Radaelli M; Filippi M
    Mult Scler; 2021 May; 27(6):841-854. PubMed ID: 32672089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS.
    Duan Y; Zhuo Z; Li H; Tian DC; Li Y; Yang L; Gao C; Zhang T; Zhang X; Shi FD; Barkhof F; Liu Y
    J Neurol Neurosurg Psychiatry; 2021 Jul; 92(7):709-716. PubMed ID: 33687975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodal characterization of gray matter alterations in neuromyelitis optica.
    Liu Y; Jiang X; Butzkueven H; Duan Y; Huang J; Ren Z; Dong H; Shi FD; Barkhof F; Li K; Wang J
    Mult Scler; 2018 Sep; 24(10):1308-1316. PubMed ID: 28741987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.
    Jurynczyk M; Probert F; Yeo T; Tackley G; Claridge TDW; Cavey A; Woodhall MR; Arora S; Winkler T; Schiffer E; Vincent A; DeLuca G; Sibson NR; Isabel Leite M; Waters P; Anthony DC; Palace J
    Acta Neuropathol Commun; 2017 Dec; 5(1):95. PubMed ID: 29208041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Diffusional Kurtosis Imaging in Differentiating Neuromyelitis Optica-Related and Multiple Sclerosis-Related Acute Optic Neuritis: Comparison With Diffusion-Weighted Imaging.
    Lu P; Yuan T; Liu X; Tian G; Zhang J; Sha Y
    J Comput Assist Tomogr; 2020; 44(1):47-52. PubMed ID: 31939881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.